Eyetech Pharmaceuticals Inc. bought a manufacturing facility to aid in the production of its lead product, Macugen. The New York company plans to use the oligonucleotide production site, which is located in Boulder, Colo., as a second source for commercial-scale production of the active pharmaceutical ingredient for Macugen (pegaptanib sodium injection). The ocular product remains under regulatory review for age-related macular degeneration, and if approved, would …

Комментариев нет:
Отправить комментарий